Zacks Investment Research lowered shares of SenesTech (NASDAQ:SNES) from a hold rating to a sell rating in a research report released on Friday morning.
According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “
SenesTech stock remained flat at $$0.71 during mid-day trading on Friday. The company had a trading volume of 114,305 shares, compared to its average volume of 826,888. The stock has a market cap of $16.64 million, a P/E ratio of -0.63 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.07 and a current ratio of 5.05. SenesTech has a 1 year low of $0.30 and a 1 year high of $2.37.
A hedge fund recently bought a new stake in SenesTech stock. Bank of Montreal Can purchased a new position in shares of SenesTech Inc (NASDAQ:SNES) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 80,000 shares of the company’s stock, valued at approximately $131,000. Bank of Montreal Can owned approximately 0.48% of SenesTech at the end of the most recent reporting period. 8.07% of the stock is currently owned by institutional investors and hedge funds.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Featured Story: Leveraged Buyout (LBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.